Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

EU flag

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The drug has been approved for rheumatoid arthritis, giant cell arteritis and other indications

- PMLiVE

Why local knowledge is key to global pharmacovigilance outcomes

The challenge for companies is to ensure their local affiliates meet local PV obligations while staying aligned with global PV requirements

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study

More than two million cases of the disease were diagnosed globally in 2022

- PMLiVE

J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

Inflammatory bowel disease affects almost one in every 100 people in the US

- PMLiVE

NHS England appoints Sir James Mackey as CEO

Mackey is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust

- PMLiVE

DE&I in clinical trials: the role of health literacy and AI

By Claire Paling and Rosamund Round

- PMLiVE

FDA approves Mirum’s Ctexli as first treatment for rare lipid storage disease CTX

The progressive genetic disorder affects up to 2,000 people in the US

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

- PMLiVE

Recce’s topical gel shows promise in acute bacterial skin and skin structure infections

ABSSSIs, including diabetic foot infections, are considered to be a significant healthcare concern

- PMLiVE

Porterhouse Medical appoints Michael Tague as president of Porterhouse Medical US

Tague most recently served as head of North America at CMC Connect

- PMLiVE

Class is the missing link in health equity strategies

By Jenny Carrington-Elson

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links